Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia

Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

(2014) Hua Lu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

(2014) M. K. Gleason et al.   BLOOD

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

(2014) A. E. Frankel et al.   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

The past and future of CD33 as therapeutic target in acute myeloid leukemia

(2014) George S. Laszlo et al.   BLOOD REVIEWS

WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy

(2014) Lindsay AM Rein et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia

(2014) C. O'Hear et al.   HAEMATOLOGICA

Targetedex vivoreduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins

(2014) Sonja Schiffer et al.   INTERNATIONAL JOURNAL OF CANCER

Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531

(2014) Alan S. Gamis et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

A new dawn for gemtuzumab ozogamicin?

(2014) Mohamed A Kharfan-Dabaja   LANCET ONCOLOGY

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

(2014) Robert K Hills et al.   LANCET ONCOLOGY

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

(2014) S J Busfield et al.   LEUKEMIA

Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

(2014) I Pizzitola et al.   LEUKEMIA

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

(2014) Simon Z. He et al.   LEUKEMIA & LYMPHOMA

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug

(2013) J. M. Rowe et al.   BLOOD

T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia

(2013) A. Mardiros et al.   BLOOD

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

(2013) J. Greiner et al.   BLOOD

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Immunotherapeutic strategies for relapse control in acute myeloid leukemia

(2013) Anna Martner et al.   BLOOD REVIEWS

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor

(2013) Sarah Tettamanti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells

(2013) Sonja Schiffer et al.   CANCER LETTERS

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

(2013) A. Wiernik et al.   CLINICAL CANCER RESEARCH

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

(2013) Roland Walter   Frontiers in Bioscience-Landmark

Acute myeloid leukaemia in adults

(2013) Felicetto Ferrara et al.   LANCET

Declining rates of treatment-related mortality in patients with newly diagnosed AML given ‘intense’ induction regimens: a report from SWOG and MD Anderson

(2013) M Othus et al.   LEUKEMIA

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system

(2013) C Arndt et al.   LEUKEMIA

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Immunotoxins: The Role of the Toxin

(2013) Antonella Antignani et al.   Toxins

T-cell adoptive immunotherapy for acute lymphoblastic leukemia

(2013) T. J. Fry et al.   Hematology-American Society of Hematology Education Program

Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004

(2012) H. Hasle et al.   BLOOD

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

(2012) J. A. Pollard et al.   BLOOD

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

(2012) M. R. Kuhne et al.   CLINICAL CANCER RESEARCH

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

(2012) G. Borthakur et al.   HAEMATOLOGICA

Gemtuzumab Ozogamicin: Time to Resurrect?

(2012) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts

(2012) Alexandre P.A. Theocharides et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Treatment of AML: resurrection for gemtuzumab ozogamicin?

(2012) Elihu Estey   LANCET

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

(2012) Sylvie Castaigne et al.   LANCET

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

(2012) S Anguille et al.   LEUKEMIA

Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin

(2011) H. F. Fernandez et al.   BLOOD

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

(2011) Simona Lapusan et al.   INVESTIGATIONAL NEW DRUGS

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

(2011) S Stamova et al.   LEUKEMIA

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting

(2011) Ingo Schubert et al.   mAbs

Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module

(2011) Slava Stamova et al.   MOLECULAR IMMUNOLOGY

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

(2010) Christoph Stein et al.   BRITISH JOURNAL OF HAEMATOLOGY

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Sequential Cytarabine and  -Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia

(2010) T. L. Rosenblat et al.   CLINICAL CANCER RESEARCH

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy

(2010) Massimo Breccia et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies

(2010) K. Rezvani et al.   HAEMATOLOGICA

Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors

(2010) V. Marin et al.   HAEMATOLOGICA

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

(2010) J. Greiner et al.   HAEMATOLOGICA

In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model

(2010) Mehmet Kemal Tur et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination

(2010) V. F. Van Tendeloo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Toxin-Based Therapeutic Approaches

(2010) Assaf Shapira et al.   Toxins

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes

(2008) B. Stahnke et al.   MOLECULAR CANCER THERAPEUTICS